AGP Picks
View all

Airline Press Releases: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Airline Press Releases.

Press releases published on November 18, 2026

EPC Space Expands Radiation-Tolerant GaN HEMT Portfolio with Plastic QFN and Hermetic Packaging Options
Study: AI Assistants Rarely Agree on Which Aviation Businesses to Recommend
Small Satellites and Micro-Launch Market Analysis Highlights Emerging Trends and Future Industry Growth Opportunities.
The Satellite Spectrum Monitoring Market is Projected to Grow Rapidly at an 11.9% CAGR Through 2030
Caplin expands Client Portal to include automated OTC commodities post-trade workflow
Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case
Nyxoah Obtient une Décision par Défaut contre Inspire Medical Systems dans une Procédure devant l’Unified Patent Court
PDMR Transaction

PDMR Transaction

Novo Nordisk Foundation commits US$60 million to strengthen CARB-X efforts against antimicrobial resistance
Zealand Pharma announces initiation of the Phase 2 ZYNERGY trial of petrelintide co-administered with enicepatide in people with obesity or overweight
مراوح ييوو الشمسية وتجارتها المتبادلة تُبقي رفوف أفريقيا عامرة
Yiwu's Solar Fans and Two-Way Trade Keep Africa's Shelves Stocked
i-payout Highlights Cost-Effective Global Payout Infrastructure for High-Volume, Low-Value Payments
ZACME Spotlights High-Capacity Kitchen Solutions as Holiday Home Baking Season Approaches
JETOUR T2 to Be Named JETOUR 20 in Australia, with First Media Preview Event Coming to Sydney
ZORWILD Details Its Custom Apparel Manufacturing Services for Brands
Lebrel Brings Uncensored DeepSeek V4.1 Flash From $0.13 per Million Input Tokens, Adds Alibaba's Qwen4-Max on Day One
Medline Inc. announces pricing of secondary offering of Class A common stock
SELLAS anuncia resultados positivos del ensayo pivotal de fase 3 REGAL, que demuestran que la vacuna inmunoterapéutica contra el cáncer galinpepimut-S (GPS) produjo una mejora estadísticamente significativa y clínicamente relevante de la supervivencia …
SELLAS Life Sciences Divulga Dados Positivos do Estudo REGAL Pivotal de Fase 3, Indicando que Galinpepimut-S (GPS), a Vacina Imunoterapêutica Contra o Câncer, Demonstrou uma Melhora Estatisticamente Significativa e Clinicamente Relevante na Sobrevida…

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Airline Press Releases

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.